“A GP will usually start treatment using a broad-spectrum antibiotic and the lab results confirm the treatment is on the right track, or it can be amended,” Dr Nanayakkara says. Around one in five ...
PHIOGEN, a biotech company developing live biotherapeutic products (LBPs) for drug-resistant and recurrent bacterial infections, is collaborating with patient research and advocacy organization Live ...